Lego Ventures and Sesame Workshop helped the children’s reading app developer close a series C round that will fund curricula development and international expansion.
Month: October 2020
Cooler Screens displays $80m round
The electronic retail display provider has emerged from stealth with series C funding from investors including M12 and Verizon Ventures.
Alucent attains $35m
Fresenius Medical Care and company founder Avera Health both took part in a round that will fund clinical trials of Alucent’s vascular disease treatment.
Your.MD scores $30m in series A
The health management app developer has completed a series A round led by Reckitt Benckiser, which had previously invested last year.
Siegel segues to chairwoman role at The Engine
Former GE Ventures CEO Sue Siegel has been selected as chairwoman of the MIT-affiliated fund and accelerator The Engine.
AI sees challenges ahead
Prize challenges are about 10 times more cost-effective than traditional projects to source innovation.
Eclypsium secures $13m in series B round
AV8’s Baris Aksoy has teamed up with his old unit Intel Capital in a round that lifted the cybersecurity software developer’s overall funding to more than $24m.
Knoma adds Rocket fuel to series A round
The online education startup formerly known as Higgler Europe has captured $27.2m in a Rocket Internet-backed round.
Uber Freight ships in $500m
Uber’s freight services subsidiary has secured series A funding from Greenbriar Equity Group in a deal valuing it at $3.3bn post-money.
Ozon opens up to IPO possibilities
The Sistema-backed e-commerce marketplace has confidentially filed for an initial public offering in the US that would value it at $3bn to $5bn.
Roblox to roll to IPO
Tencent-backed online gaming platform developer Roblox is in talks over an IPO or direct listing at a valuation of up to $8bn.
Canadian Solar to cash $261m for spinoff
The cash will go to the solar energy provider’s solar modules and systems subsidiary, CSI Solar, in advance of a planned IPO in China.
C4 Therapeutics blows on to public markets
The Roche, Novartis and Kraft Group-backed cancer therapy developer raised $182m in an upsized IPO where it floated above its range.
Carmot curates $47m series C round
Amgen has invested in Carmot Therapeutics having previously licensed a cancer drug candidate from the company that is currently in phase 2 clinical trials.